Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Cardiology Cardiology for November/December 2020 Sac/val heart failure benefit extends to diabetes patients, Sedentary postmenopausal women have higher heart failure risk, Experts disagree with USPSTF’s take on pediatric blood pressure screening, GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit, Don’t miss cardiovascular risk factors in transgender patients, More must reads Cardiology for September/October 2020 Collaborative care model linked to better outcomes in pregnant women, Artificially sweetened drinks add to CVD risk, Cardiogenic shock rate soars in COVID-positive ACS, Benefit of rivaroxaban after limb revascularization greatest in those with comorbid CAD, Teen affective disorders raise risk for midlife acute MI, More must readsCardiology for July/August 2020 DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes, RATE-AF trial boosts digoxin for rate control in permanent AFib teaser, EMPEROR-Reduced: Empagliflozin's HFrEF benefit solidifies class effects, Nine antihypertensive drugs associated with reduced risk of depression, Since COVID-19 onset, admissions for MI are down, mortality rates are up, More must readsCardiology for May/June 2020 Early hypertensive disorders in pregnancy linked to obesity, T2D plus heart failure packs a deadly punch, Frequent hypoglycemic episodes raise cardiac event risk, DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients, Smart phones boosted compliance for cardiac device data transmission, More must readsCardiology for March/April 2020 ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients, HFpEF: Gender difference in sacubitril/valsartan response remains mystery, Enhanced team-based CVD care found to benefit diabetes patients, New lipid-lowering drug class slashes LDL in HoFH patients, Alirocumab effective in homozygous FH, More must readsPages1 2 3 4 5 6 7 last »
